Pharmaceutical Manufacturers’ Invoice Pricing and Rebate Policies
First written in FY2016. 5 of 7 entries say "Restated". Latest entry: FY2026.
3 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「To obtain rebates and sales incentives, the Group periodically reviews its trading terms with manufacturers and proposes initiatives to manufacturers.」
It continues to review trading terms and make proposals in response to manufacturers' rebate and sales incentive policies. - FY2022RestatedAnnual report
「To obtain rebates and sales incentives, the Group periodically reviews its trading terms with manufacturers and proposes initiatives to manufacturers.」
It continues to review trading terms and make proposals in response to manufacturers' rebate and sales incentive policies. - FY2020MitigatedAnnual report
「To obtain rebates and sales incentives, the Group periodically reviews its trading terms with manufacturers and proposes initiatives to manufacturers.」
In response to the risks arising from manufacturers' rebate and sales incentive policies, it explicitly states that it reviews trading terms and proposes initiatives. - FY2019RestatedAnnual report
「Some pharmaceutical manufacturers changed their wholesale price levels and the payment criteria for rebates and sales incentives in response to the new drug pricing system. These changes themselves, or the degree to which the Group meets the payment criteria, may affect gross profit and, consequently, the Group's results.」
It continues to identify the risk that changes in pharmaceutical manufacturers' wholesale prices, rebates and other terms may affect results. - FY2018RestatedAnnual report
「Some pharmaceutical manufacturers changed their wholesale price levels and the payment criteria for rebates and sales incentives in response to the new drug pricing system. These changes themselves, or the degree to which the Group meets the payment criteria, may affect gross profit and, consequently, the Group's results.」
It continues to identify the risk that changes in manufacturers' wholesale prices, rebates and other terms may affect results. - FY2017RestatedAnnual report
「Some pharmaceutical manufacturers changed their wholesale price levels and the payment criteria for rebates and sales incentives in response to the new drug pricing system. These changes themselves, or the degree to which the Group meets the payment criteria, may affect gross profit and, consequently, the Group's results.」
It reiterates the risk that changes in manufacturers' wholesale prices, rebates and other terms may affect results. - FY2016First statedAnnual report
「Some pharmaceutical manufacturers changed their wholesale price levels and the payment criteria for rebates and sales incentives in response to the new drug pricing system. These changes themselves, or the degree to which the Group meets the payment criteria, may affect gross profit and, consequently, the Group's results.」
It identifies changes in wholesale prices and rebates, as well as the degree to which payment criteria are met, as risks.